Sravnitel'noe issledovanie effektivnosti otechestvennogo generika i original'nogo preparata zoledronovoy kisloty u patsientok s maloenergeticheskimi perelomami tel pozvonkov i postmenopauzal'nym osteoporozom

A prospective comparative study in two comparable clinical groups of women with low-energy compression fractures of the vertebral bodies on the background of postmenopausal osteoporosis was performed; the study has shown comparable efficacy and safety of anti-osteoporotic pharmacotherapy with domestic generics Rezoklastin FS (5 mg/6.25 ml), and the original drug of zoledronic acid Aclasta (5 mg/100 ml). The use of Rezoklastin FS is accompanied by relatively lower incidence of influenza-like effect, a marked positive effect on bone mineral density, confirmed by the results of dual energy X-ray densitometry, as well as the ability to prevent the occurrence of repeated low-energy vertebral compression fractures at 1-year follow-up. This allows to recommend the domestic drug of zoledronic acid Rezoklastin FS as an effective medicine for the secondary prevention of repeated vertebral osteoporotic fractures in women with postmenopausal osteoporosis.

osteoporosis, compression fractures of the vertebral bodies, bisphosphonates, zoledronic acid, Rezoklastin FS